Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

August 27, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Endometrial Cancer Treatment via Adjuvant Radiotherapy

Increasing life expectancy in cancer patients

Tocilizumab and Sarilumab receives WHO Approval for critically-ill Patients

Endometrial Cancer Treatment via Adjuvant Radiotherapy
  • BiotechToday
  • World

Endometrial Cancer Treatment via Adjuvant Radiotherapy

bioxone July 9, 2021July 9, 2021

Shayan Ahmed, Jamia Millia Islamia, New Delhi

Endometrial cancer (EC) is the most prevalent gynaecological cancer, with endometrioid adenocarcinoma accounting for the majority of cases. Surgical intervention is considered to be the most radical type of treatment. Therefore, adjuvant radiotherapy is advised for certain patient subgroups for endometrial cancer treatment. To remove microscopic disease in the locoregional area, radiation modality includes pelvic external beam radiotherapy (EBRT) to the pelvis and vaginal brachytherapy (VBT) to the vaginal cuff. The choice of adjuvant radiation modality is dependent on the patient’s risk profile. The best adjuvant radiation method for patients with stage I to II high-risk endometrioid cancer is still up for debate.

High-risk endometrial cancer is marked by a higher incidence of pelvic recurrence and distant metastases, both of which contribute to the group’s poor prognosis. For high-risk patients with stage I to II endometrioid adenocarcinoma, recent research compares the oncologic results of EBRT, EBRT+VBT, and VBT alone. 

VBT was successful in preventing vaginal stump recurrence, whereas pelvic radiotherapy allowed for treatment of both the vaginal and pelvic lymphatic drainage areas. In the EBRT+VBT group, overall survival was considerably improved. The survival results of the EBRT and EBRT+VBT regimens were not significantly different. For intermediate- or high-intermediate-risk patients, vaginal brachytherapy alone is presently indicated. The best adjuvant radiation modality for patients with high-risk endometrioid cancer following complete hysterectomy, bilateral salpingo-oophorectomy, and main lymphadenectomy was investigated in this new study. After pelvic radiotherapy, the vaginal recurrence incidence among profoundly myometrial invasive Grade 3 patients was just 5%. No evidence adding a vaginal cuff brachytherapy boost to pelvic radiation improved pelvic control or mortality in cervical involvement patients. The local-regional control rate of EBRT alone was satisfactory for high-risk individuals. The rate of pelvic and vaginal control, as well as overall survival, appeared to be unaffected by a VBT increase. However, whether external and internal irradiation should be paired is still up for discussion.

The results revealed that patients who received pelvic irradiation had a lower locoregional recurrence rate and a lower distant failure rate than those who had VBT alone. This explains the significance of EBRT in high-risk groups. Furthermore, like in previous trials, distant metastases were the leading cause of failure in this one. Chemotherapy may help with survival by eradicating systemic micro-metastases, particularly distant metastases. Chemotherapy, however, did not significantly enhance survival in this study. In terms of toxicity, all individuals withstood acute toxicity well. During the follow-up period following therapy, no adverse events of Grade 3 or higher were discovered. However, additional data is required, as well as randomized studies.

Also read: Increasing life expectancy in cancer patients

Source: Wang, W., Zou, L., Wang, T., Liu, Z., He, J., Sun, X., Zhong, W., Zhao, F., Li, X., Li, S., Zhu, H., Ma, Z., Sun, S., Jin, M., Zhang, F., Hou, X., Wei, L., & Hu, K. (2021). Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis. BMC cancer, 21(1), 774. https://doi.org/10.1186/s12885-021-08524-x 

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

About Author: Shayan Ahmed is currently pursuing a Master of Science degree in Microbiology from the Department of Biosciences, Jamia Millia Islamia, New Delhi. His area of research interest lies in antibiotic resistance and associated molecular mechanisms. His recent work was focused on understanding colistin resistance patterns in the environment, particularly in water bodies.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Adjuvant Radiotherapy cancer cancer treatment Cervical Cancer endometrial cancer External Beam Radiotherapy Pelvic Irradiation Pelvic Radiotherapy Radiotherapy Vaginal Brachytherapy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Tocilizumab and Sarilumab receives WHO Approval for critically-ill Patients

BioTech Today July 9, 2021

Agrima Bhatt, Rajasthan University Current Scenario The emergence of coronavirus from 2019 till now has led to a global healthcare crisis all over the world. Recent data of COVID-19 shows data as of July 7 having 184,324,026 confirmed cases and 3,992,680 deaths. Although vaccination has started to pick up pace in many countries, the risk […]

Tocilizumab and Sarilumab

Related Post

  • BiotechToday
  • World

New Research Reveals Androgen Receptor promotes Cancer

bioxone March 3, 2021March 3, 2021

Thota Kanishka Rao, Amity University Kolkata Prostate cancer growth (PCa) is the most common disease after skin disease and the subsequent driving reason for cancer death in men. Androgen receptor (AR) flagging is fundamental for PCa cell development and endurance. Hence, androgen development treatment (ADT) is the standard treatment for advanced/metastatic PCa.  Notwithstanding, patients unavoidably […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Butterflies need cool shades to survive!

bioxone September 26, 2020September 26, 2020

Richismita Hazra, Amity University Kolkata Climatic variations affect the abundance, spread, and phenology of species. Removal of microclimates that the butterflies need to survive, along with drastic climatic variations has led to extreme weather alterations and temperature fluctuations. This has affected the survival of butterflies that are ectotherms and hence dependent on external sources of […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Is hypergastrinemia risking gastric adenocarcinoma?

bioxone October 26, 2020October 25, 2020

Arjama Roy, Amity University Kolkata Gastric adenocarcinoma is the 5th most typical cancer worldwide. The main risk factor for non-cardia gastric adenocarcinoma is atrophic gastritis. It is because of infection with Helicobacter pylori (H pylori). However, in Western populations, due to the decreasing pervasiveness of H pylori infections, the incidence of gastric adenocarcinoma has declined […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy